The Team, the Team, the Team: Creating a Short Bowel Syndrome Medical NeighborhoodPremiere Date: Tuesday, April 26, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- ABP (MOC)
- ABS (CC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Dietetic Registration (CDR)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, April 27, 2023
Note: Credit Is No Longer Available
|Miguel Regueiro, MD, AGAF, FACG, FACP (Moderator)
Chair, Digestive Disease and Surgery
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Professor, Department of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
|Kishore R. Iyer, MBBS, FRCS (Eng), FACS
Director, Intestinal Rehab & Transplant Program
Program Director, Transplant Surgery Fellowship
Professor of Surgery & Pediatrics
Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai
New York, NY
|Donald F. Kirby, MD, FACP, FACN, FACG, AGAF, FASPEN, CNSC, CPNS
Director, Center for Human Nutrition
Medical Director, Intestinal Transplant Program
Professor of Medicine
Although short bowel syndrome (SBS) remains a relatively rare disorder, the number of cases has doubled in the past 40 years. Due to this increased disease incidence and a projected shortage of gastroenterologists, an interdisciplinary approach is needed that is inclusive of primary care physicians, PAs, and nurse practitioners who are likely to be recruited to care for this patient population.
In this CME Outfitters Live and OnDemand webcast, expert faculty in SBS will discuss integrating an interdisciplinary team to optimize the management of patients with SBS, with a focus on applying efficacy and safety data to treatment decision-making and implementing best practices from state-of-the-art intestinal rehabilitation centers in the community to improve access and care.
At the end of this CE activity, participants should be able to:
- Integrate an interdisciplinary team to optimize the management of patients with SBS.
- Apply efficacy and safety data to treatment decision-making for patients with SBS.
- Implement best practices from state-of-the-art SBS/IR centers in the community to improve access and care for patients with SBS.
Supported by an educational grant from Takeda Pharmaceuticals, U.S.A., Inc.
Gastroenterologists, surgeons, pediatricians, internists, primary care physicians, PAs, nurse practitioners, nurses, pharmacists, social workers, dietitians, psychologists, and feeding therapists
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Regueiro reports the following financial relationships:
Advisory Board and Consultant: AbbVie Inc.; Alfasigma, S.p.A.; Allergan; Amgen Inc.; Celgene Corporation; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Miraca Laboratories; Pfizer Inc.; Prometheus Biosciences; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; TARGET PharmaSolutions, Inc.; and UCB, Inc.
Research Support: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Royalties: Wolters Kluwer Health as Author/Editor of UpToDate
Unrestricted Educational Grants: AbbVie Inc.; Celgene Corporation; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.
Dr. Iyer reports the following financial relationships:
Consultant: Hanmi Pharmaceutical, Co., Ltd.; Ipsen Pharma; Takeda Pharmaceuticals U.S.A., Inc.; and VectivBio
Grants:Takeda Pharmaceuticals U.S.A.
Research Support:Takeda Pharmaceuticals U.S.A.; VectivBio; and Zealand Pharma A/S
Dr. Kirby reports the following financial relationships:
Advisory Board: OWYN, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and VectivBio
The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).